Neuroendocrine Regulation and Oxidative Stress Parameters in Women of Reproductive Age of Different Ethnic Groups with Hyperandrogenic Phenotypes of Polycystic Ovary Syndrome
- Authors: Darenskaya M.A.1, Belenkaia L.V.1, Kolesnikov S.I.1, Sholokhov L.F.1, Danusevich I.N.1, Lazareva L.M.1, Nadeliaeva I.G.1, Kolesnikova L.I.1
-
Affiliations:
- Scientific Centre for Family Health and Human Reproduction Problems
- Issue: Vol 74, No 2 (2025)
- Pages: 23-32
- Section: Original study articles
- Submitted: 13.05.2024
- Accepted: 07.02.2025
- Published: 26.05.2025
- URL: https://journals.eco-vector.com/jowd/article/view/630445
- DOI: https://doi.org/10.17816/JOWD630445
- EDN: https://elibrary.ru/BQJDBV
- ID: 630445
Cite item
Abstract
BACKGROUND: Polycystic ovary syndrome is considered a pressing problem that significantly reduces the quality of life of women. Patients with androgenic phenotypes of this disease are allocated to a special observation group for the development of metabolic disorders and related complications. It has now been proven that there are ethnic differences in the manifestations of polycystic ovary syndrome, but its hormonal and metabolic aspects in representatives of the indigenous ethnic groups of Eastern Siberia have not yet been assessed. Understanding these processes will contribute to the personalization of the prevention and treatment of polycystic ovary syndrome in reproductive age.
AIM: The aim of this study was to determine changes in the parameters of neuroendocrine regulation and oxidative stress in reproductive-age women of different ethnic groups with hyperandrogenic phenotypes of polycystic ovary syndrome.
METHODS: This study included 186 women of reproductive age (18–44 years old) living in the Irkutsk region and the Republic of Buryatia. Groups of women with polycystic ovary syndrome of Russian (n = 67) and Buryat (n = 27) ethnic groups and corresponding control groups (n = 68 and n = 24) were formed.
RESULTS: Both Russian and Buryat ethnic patients with polycystic ovary syndrome had elevated testosterone levels, free androgen indices, and dehydroepiandrosterone sulfate levels, as well as reduced sex hormone-binding globulin levels relative to the corresponding control values. At the same time, Russian patients also had increased anti-Müllerian hormone levels. Oxidative stress parameters in the group of Russian ethnic women with polycystic ovary syndrome were expressed by elevated retinol levels, while in Buryat ethnic women, they were expressed by increased values of thiobarbituric acid products, as well as reduced glutathione and α-tocopherol levels.
CONCLUSION: The data obtained indicate the presence of dramatic changes in neuroendocrine regulation in women with polycystic ovary syndrome, regardless of ethnicity. At the same time, compensatory shifts in the antioxidant defense system in women of the Russian ethnicity and activation of lipid peroxidation in patients of the Buryat ethnic group were revealed. The results also indicate the need to assess and control the levels of these metabolites in women with polycystic ovary syndrome, taking into account their ethnicity.
Full Text

About the authors
Marina A. Darenskaya
Scientific Centre for Family Health and Human Reproduction Problems
Author for correspondence.
Email: marina_darenskaya@inbox.ru
ORCID iD: 0000-0003-3255-2013
SPIN-code: 3327-4213
Dr. Sci. (Biology), Professor of the Russian Academy of Sciences
Russian Federation, IrkutskLiliia V. Belenkaia
Scientific Centre for Family Health and Human Reproduction Problems
Email: drblv@mail.ru
ORCID iD: 0000-0003-4904-3709
SPIN-code: 6272-2718
MD, Cand. Sci. (Medicine)
Russian Federation, IrkutskSergey I. Kolesnikov
Scientific Centre for Family Health and Human Reproduction Problems
Email: sikolesnikov1@rambler.ru
ORCID iD: 0000-0003-2124-6328
SPIN-code: 1752-6695
MD, Dr. Sci. (Medicine), Professor, Academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation
Russian Federation, IrkutskLeonid F. Sholokhov
Scientific Centre for Family Health and Human Reproduction Problems
Email: lfshol@mail.ru
ORCID iD: 0000-0003-3588-6545
SPIN-code: 4138-8991
MD, Dr. Sci. (Medicine), Professor
Russian Federation, IrkutskIrina N. Danusevich
Scientific Centre for Family Health and Human Reproduction Problems
Email: irinaemails@gmail.com
ORCID iD: 0000-0002-8862-5771
SPIN-code: 6289-3358
MD, Dr. Sci. (Medicine)
Russian Federation, IrkutskLyudmila M. Lazareva
Scientific Centre for Family Health and Human Reproduction Problems
Email: lirken_@mail.ru
ORCID iD: 0000-0002-7662-8529
SPIN-code: 7056-7495
MD, Cand. Sci. (Medicine)
Russian Federation, IrkutskIana G. Nadeliaeva
Scientific Centre for Family Health and Human Reproduction Problems
Email: ianadoc@mail.ru
ORCID iD: 0000-0002-5747-7315
SPIN-code: 7766-5841
MD, Cand. Sci. (Medicine)
Russian Federation, IrkutskLubov I. Kolesnikova
Scientific Centre for Family Health and Human Reproduction Problems
Email: kolesnikova20121@mail.ru
ORCID iD: 0000-0003-3354-2992
SPIN-code: 1584-0281
MD, Dr. Sci. (Medicine), Professor, Academician of the Russian Academy of Sciences, Honored Scientist of the Russian Federation
Russian Federation, IrkutskReferences
- Walker W, Lizneva DV, Belenkaia LV, et al. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol. 2019;71(3):211–225. EDN: KJLFAU doi: 10.23736/S0026-4784.19.04404-6
- Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. EDN: XEEHQZ doi: 10.1038/nrdp.2016.57
- Rodgers RJ, Suturina L, Lizneva D, et al. Is polycystic ovary syndrome a 20th сentury phe-nomenon? Med Hypotheses. 2019;124:31–34. EDN: THRZEF doi: 10.1016/j.mehy.2019.01.019
- Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycys-tic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. EDN: OGNSMX doi: 10.1093/humrep/dey256
- Adamyan LV, Andreeva EN, Gasparyan SA, et al. Polycystic ovary syndrome in reproductive age (contemporary approaches to diagnosis and treatment). Reprod Health Problems. 2018;24(S6):708–713. (In Russ.) EDN: CMAAPY
- Komarov EK, Mikhina EA, Osinovskaya NS. Hormonal and metabolic characteristics of an-drogenic phenotypes of polycystic ovary syndrome and congenital adrenal hyperplasia with various polymorphic variants of the CYP17A1 gene. Journal of Obstetrics and Women’s Diseases. 2020;69(1):27–36. EDN: QXGJGJ doi: 10.17816/JOWD69127-36
- Nehir Aytan A, Bastu E, Demiral I, et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(9):709–713. doi: 10.3109/09513590.2016.1155208
- Adamyan LV, Andreeva EN, Absatarova YuS, et al. Clinical guidelines «polycystic ovary syndrome». Endocrinology Issues. 2022;68(2):112–127. doi: 10.14341/probl12874 EDN: WNWJWN
- Abashova EI, Shalina MA, Misharina EV, et al. Clinical features of polycystic ovary syn-drome phenotypes in women with normogonadotropic anovulation in reproductive age. Journal of Obstetrics and Women’s Diseases. 2019;68(3):7–14. EDN: ONYBFM doi: 10.17816/JOWD6837-14
- Absatarova YuS, Evseeva YuS, Andreeva EN. Neuroendocrine features of the pathogenesis of polycystic ovary syndrome (literature review). Problems of Endocrinology. 2023;69(5):107–114. EDN: AFGZAA doi: 10.14341/probl13350
- Krusko OV, Rashidova MA, Brichagina, et al. Features of the functional state of the hypothalamic-pituitary-ovarian-adrenal system and the processes of lipid peroxidation - antioxidant protectionin women with polycystic ovary syndrome in the early reproductive period. Acta Biomedica Scientifica. 2020;5(6):20–26. EDN: YCAQBF doi: 10.29413/ABS.2020-5.6.2
- Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2019;25(4):486–504. doi: 10.1093/humupd/dmz014
- Kolesnikova LI, Kolesnikov SI, Darenskaya MA, et al. Activity of LPO processes in women with polycystic ovarian syndrome and infertility. Bulletin of Experimental Biology and Medicine. 2017;162(3):320–322. EDN: YGHXBD doi: 10.1007/s10517-017-3605-5
- Papalou O, Victor VM, Diamanti-Kandarakis E. Oxidative Stress in polycystic ovary syndrome. Curr Pharm Des. 2016;22(18):2709–2722. EDN: WUPQKL doi: 10.2174/1381612822666160216151852
- Ryu KJ, Park H, Kim MS, et al. Risk of cardiocerebrovascular diseases is increased in Korean women with polycystic ovary syndrome: a nationwide cohort study. Sci Rep. 2024;14(1):1055. EDN: FUPLCC doi: 10.1038/s41598-023-50650-y
- Wolf WM, Wattick RA, Kinkade ON, et al. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018;15(11):2589. doi: 10.3390/ijerph15112589
- Lazareva LM, Sharifulin EM, Belenkaya LV, et al. PCOS in reproductive age: phenotypic diversity and diagnostic approaches (literature review). Doctor.Ru. 2020;19(6):50–56. EDN: NPZZUZ doi: 10.31550/1727-2378-2020-19-6-50-56
- Zhao X, Ni R, Li L, et al. Defining hirsutism in Chinese women: a cross-sectional study. Fertil Steril. 2011;96(3):792–796. doi: 10.1016/j.fertnstert.2011.06.040
- Kolesnikova LI, Darenskaya MA, Grebenkina LA, et al. ethnic issues in medical research (literature review). Bulletin of the East Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences. 2013;4(92):153–159. (In Russ.)
- Darenskaya MA Characteristics of metabolic responses in the indigenous and migrant populations of the North and Siberia. Bulletin of the East Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences. 2014;2(96):97–103. (In Russ.)
- Belenkaya LV, Suturina LV, Darenskaya MA, et al. Age-related determinants of metabolic syndrome in women of reproductive age from the main ethnic groups of the Baikal region. Acta Biomedica Scientifica. 2023;8(4):39–48. EDN: GYAAJE doi: 10.29413/ABS.2023-8.4.5
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 con-sensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098
- Darenskaya MA., Belenkaya LV, Atalyan AV, et al. Оxidative stress reactions in women of reproductive age with metabolic syndrome. Bulletin of Experimental Biology and Medicine. 2023;174(5):601–604. EDN: CJZPXL doi: 10.1007/s10517-023-05754-w
- Liao B, Qiao J, Pang Y. Central Regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Front Endocrinol (Lausanne). 2021;(12):667422. EDN: WJVLIL doi: 10.3389/fendo.2021.667422
- Sacha CR, Chavarro JE, Williams PL, et al. Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center. J Assist Reprod Genet. 2020;37(11):2757–2766. EDN: LQTDND doi: 10.1007/s10815-020-01956-7
- Chang WY, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83(6):1717–1723. doi: 10.1016/j.fertnstert.2005.01.096
- Salinas I, Sinha N, Sen A. Androgen-induced epigenetic modulations in the ovary. J Endocrinol. 2021;249(3):53–64. EDN: LEDAFT doi: 10.1530/JOE-20-0578
- Boyarsky KY, Gaidukov SN, Mashkova EA. The role of AMH measurement in normal ovarian function and different gynecological diseases. Journal of Obstetrics and Women’s Diseases. 2009;58(3):75–85. EDN: KWSDQZ
- Cimino I, Casoni F, Liu X, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun. 2016;(7):10055. doi: 10.1038/ncomms10055
- Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on as-sessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361–3373. EDN: FPGJJH doi: 10.1210/clinem/dgaa513
- Liu XY, Yang YJ, Tang CL, et al. Elevation of antimüllerian hormone in women with poly-cystic ovary syndrome undergoing assisted reproduction: effect of insulin. Fertil Steril. 2019;111(1):157–167. doi: 10.1016/j.fertnstert.2018.09.022
- Silva MSB, Decoster L, Trova S, et al. Female sexual behavior is disrupted in a preclinical mouse model of PCOS via an attenuated hypothalamic nitric oxide pathway. Proc Natl Acad Sci USA. 2022;119(30):e2203503119. EDN: NYUPXU doi: 10.1073/pnas.2203503119
- Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone repro-grams the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24(6):834–846. EDN: YIPDBJ doi: 10.1038/s41591-018-0035-5
- di Clemente N, Racine C, Rey RA. Anti-Müllerian hormone and polycystic ovary syndrome in women and its male equivalent. Biomedicines. 2022;10(10):2506. EDN: LAOPLV doi: 10.3390/biomedicines10102506
- Wang L, Li J. The value of serum-free androgen index in the diagnosis of polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2021;47(4):1221–1231. EDN: CDAFLT doi: 10.1111/jog.14681
- Zhang D, Gao J, Liu X, et al. Effect of three androgen indexes (FAI, FT, and TT) on clini-cal, biochemical, and fertility outcomes in women with polycystic ovary syndrome. Reprod Sci. 2021;28(3):775–784. EDN: RUTIKV doi: 10.1007/s43032-020-00316-1
- Abdalla MA, Deshmukh H, Mohammed I, et al. The effect of free androgen index on the quality of life of women with polycystic ovary syndrome: a cross-sectional study. Front Physiol. 2021;(12):652559. EDN: HRGLTB doi: 10.3389/fphys.2021.652559
- Dokras A, Sarwer DB, Allison KC, et al. Weight Loss and lowering androgens predict im-provements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101(8):2966–2974. doi: 10.1210/jc.2016-1896
- Benjamin JJ, K M, Koshy T, et al. DHEA and polycystic ovarian syndrome: meta-analysis of case-control studies. PLoS One. 2021;16(12):e0261552. EDN: LGDPXJ doi: 10.1371/journal.pone.0261552
- de Medeiros SF, Barbosa BB, de Medeiros AKLWY, et al. Differential effects of various androgens on polycystic ovary syndrome. Horm Metab Res. 2021;53(5):341–349. EDN: VMZKYW doi: 10.1055/a-1422-3243
- Huang Z, Yong EL. Ethnic differences: Is there an Asian phenotype for polycystic ovarian syndrome? Best Pract Res Clin Obstet Gynaecol. 2016;37:46–55. doi: 10.1016/j.bpobgyn.2016.04.001
- Ding T, Hardiman PJ, Petersen I, et al. The prevalence of polycystic ovary syndrome in re-productive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96351–96358. doi: 10.18632/oncotarget.19180
- Choi W, Park JS, Oluwatobiloba A, et al. Differences of polycystic ovary syndrome (PCOS) effects among Asian and Caucasian women. Asian J Med Health. 2021;19(8):29–36. doi: 10.9734/AJMAH/2021/v19i830354
- Sendur SN, Yildiz BO. Influence of ethnicity on different aspects of polycystic ovary syn-drome: a systematic review. Reprod Biomed Online. 2021;42(4):799–818. EDN: ULEAVG doi: 10.1016/j.rbmo.2020.12.00645
- Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: ethnic dif-ferences. J Obstet Gynaecol Res. 2019;45(12):2330–2337. doi: 10.1111/jog.14132
- Kolesnikova LI, Darenskaya MA, Grebenkina LA, et al. Characterization of lipoperoxidation processes in women of different populations with hyperprolactinemia and infertility. Journal of Obstetrics and Women’s Diseases. 2011;60(5):55–61. EDN: OKFKAF
- Vasyuk YuA, Sadulaeva IA, Yushchuk IN, et al. Retinol-binding protein as a marker of car-diovascular risk in patients with arterial hypertension and obesity. Russian Journal of Cardiology. 2018;4(156):14–18. EDN: XMHFPF doi: 10.15829/1560-4071-2018-4-14-18
- Rudnicka E, Duszewska AM, Kucharski M, et al. Oxidative stress and reproductive function: Oxidative stress in polycystic ovary syndrome. Reproduction. 2022;164(6):145–154. EDN: VCQQKK doi: 10.1530/REP-22-0152
- Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and can-cers. Oxid Med Cell Longev. 2016:8589318. EDN: VFULVJ doi: 10.1155/2016/8589318
- Ezeh U, Ida Chen YD, Azziz R. Racial and ethnic differences in the metabolic response of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2020;93(2):163–172. EDN: DGCJNY doi: 10.1111/cen.14193
- Chahal N, Quinn M, Jaswa EA, et al. Comparison of metabolic syndrome elements in White and Asian women with polycystic ovary syndrome: results of a regional, American cross-sectional study. FS Rep. 2020;1(3):305–313. EDN: HYOJIB doi: 10.1016/j.xfre.2020.09.008
- Rahmatnezhad L, Moghaddam-Banaem L, Behrouzi Lak T, et al. Free androgen index (FAI)’s relations with oxidative stress and insulin resistance in polycystic ovary syndrome. Sci Rep. 2023;13(1):5118. EDN: SREFXQ doi: 10.1038/s41598-023-31406-0
- Lankin VZ, Tikhaze AK, Kosach VYa, et al. Modification of low-density lipoproteins by low-molecular-weight carbonyl products of free radical oxidation of lipids and carbohydrates plays a key role in atherosclerotic damage to the vascular wall and endothelial dysfunction. Acta Biomed Sci. 2023;8(3):14–24. EDN: CVPZCX doi: 10.29413/ABS.2023-8.3.2
- Bafor EE, Uchendu AP, Osayande OE, et al. Ascorbic acid and alpha-tocopherol contrib-ute to the therapy of polycystic ovarian syndrome in mouse models. Reprod Sci. 2021;28(1):102–120. EDN: BWXJXI doi: 10.1007/s43032-020-00273-9
- Mutalip SSM, Nordin M, Mohamed R, et al. Vitamin E and polycystic ovary syndrome: a review on the reported clinical trials. Pharmacophore. 2021;12(3):60–63. EDN: SZKEJU doi: 10.51847/wiBzbb8IKA
- Izadi A, Ebrahimi S, Shirazi S, et al. Hormonal and metabolic effects of coenzyme Q10 and/or vitamin E in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104(2):319–327. EDN: ZOOSLX doi: 10.1210/jc.2018-01221
- Iervolino M, Lepore E, Forte G, Laganà AS, et al. Natural molecules in the management of polycystic ovary syndrome (PCOS): an analytical review. Nutrients. 2021;13(5):1677. EDN: XWXRTB doi: 10.3390/nu13051677
- Kolesnikova LI, Semenova NV, Labygina AV, et al. Evaluation of antioxidant status in women with endocrine infertility. Journal of Obstetrics and Women’s Diseases. 2010;59(4):57–60. EDN: NEBLFF
Supplementary files
